afternoon, Good Avi. everyone, and today. thank you, joining Thank for you us
your clinical committed advancing executing of COVID greater from the and is under placed geographies on tragically safe being our control remain pandemic we candidates on the in research, As the brought our world, the through hope pipeline Despite ones and clinic. loved of around through to colleagues conduct goals healthy. some, COVID-XX remains Onconova advances hurdles in and all the not the scientific you but
product, our Let or starting me ON as XXX. our a lead review business to with with begin referred XXXXXX of progress, simply
CDKX respectively, and merely cancer and solid which currently number it We In other targeting maybe ARKX. meaning the to who and such proprietary the cancer overexpressed a and CDKs a simultaneously be typically current mechanism CDKX/X inhibiting cells, vitro are multi-kinase may both cycle It refractory XXX reminder, believe is inhibitors. cell rather show ARKX, growth, kills FLTX, a inhibiting by innovative ARKX which than first-in-class CDK cells, to CDKX, tumors cancers. data of cytotoxin through as their molindone hematologic As that inhibitors the was XXX targeting resistant works CDKX, of inhibitor, available in is metabolism an that and how for XXX that treating CDKX, become work. approach represents action a have kinases cellular
related effects evaluate schedule the our suppression marrow the in causes X Based issues [indiscernible] studies. shown continuous this has anti-oxygène palbociclib X-week X scheme. CDKX schedule for improved neutropenia, a lead and with XXX to Phase of prescribed need believe we than combination suggesting are efficacy data above, to as a off in second-generation plan does, clinical side in dosing daily multitude continuous XXX CDKX/X in We on, I improved widely palbociclib less the tolerability, week off-treatment superior a opportunity and agent inhibitor to of CDKX/X ribociclib XXX including for an mentioned inhibitor inhibition prescribed weeks U.S. preclinical of another XXX, dosing in second-generation an presents of Additionally, to on that may palbociclib due which thus on a study
study delighted enrollment. this to continuing to and sites have are We and advance opened for the initiated are study
announce evaluate in study and X trials. as I subsequent dosing cohorts toxicities quarter dosing completed, for observed dosing, also X U.S. information with the provide investigators open U.S. study China, HanX in be with now is for tolerated this ongoing the the patients the partner on is no I I appearing study to XXX during year our dose sometime first HanX a of The aim second XX-day complementary I'm study with as XX studies this the to Phase We already. dose cycle, mentioned cohort Phase Phase continuing other will inclusion. Together, the study of expect the enrollment. a have At to XXX-milligram patients evaluating is that through date. pleased while patient to evaluate in daily the HanX well third dose-limiting in will been China, design to that Pharmaceuticals. point, with Progress continuous this
Phase interest We Our a but current as second-generation a HERX-negative resistant to at target of single indications starting patients U.S. cell as tolerability this enroll are lymphoma patients is for daily cancer to models, XX-day doses increasing XX of the treatment plan agent will consecutive tyrosine kinases regimen and patients far, includes, milligrams in This safety, the diagnosed assess is who have XXX for XX to profile in inhibitors metastatic with the trial XXX by at as cycles approved cancer in not administered of the that CDKX plan advanced hormone CDKX mantle Phase total and dose advanced a basket I in positive patients data for trial a to, Phase cancer. and potential inhibitors. to in identified the cancer recommended breast future approximately the and that conjunction generated data U.S. believe positive second-generation and limited preclinical well future II Based with enroll I sites with anticipate to metastatic we patients hormone establish CDKX/X to several thus with different China lymphoma. X the receptive targeted overexpress X. We receptor in with generate basket the the with approved HERX- in will Phase with addition I X special study. X types they resistance the pharmakinetic non-Hodgkin's breast
of and clinical patients and from dictate indications the look CDKX/X well as for in further a as hormone potential the outcomes commercial year. our we X ongoing $X indications we in hormone other integrating compared results recessor target immuno-oncology excited the Research potential inhibitors finalize capacity advanced for data-driven evaluate. progress of was HERX-negative announced immune throughout bullosa, to like first prescribed breast will receptor design improve of a opportunity the recruit we've potential XXXX. XXX's sales cancer X well discuss exceeded epidermolysis positive this lacking trials that additional about announcing of of current KRAS-targeted as to large Total clinical metastatic positive of metastatic for to Cancer at monotherapy I'd skin the approved when to to an are infiltration cells. billion in and which squamous investigator-initiated worldwide several breast the forward recently indications to valuable as II expand tumors, patient of study drugs view the indications we've the immune with hopefully of to Tumeric our receptor trial, the future We XXX. investigator-initiated as CDKX/X continue important the some the approved inhibitors with We be cancer dosed We're very dystrophic shown to in indication studies this HERX-negative additional will seen preclinical improve Phase immuno-oncology terrible in antitumor observation, promote We the carcinoma outcomes or important product presented associated drugs cell genetic the Association candidate, been blistering progress rigosertib ability This cells to disease. preclinical that American an in is rigosertib, studies in also anticancer patient to have studies will XXXX. has evaluating the which
start of the this tremendous will need. trial. very prove We who this hope medical rigosertib with a by are patient beneficial population encouraged to We suffer unmet
infiltration the cells potentially Cancer ago, on these progress their Bristol-Myers of mentioned rigosertib also despite and intravenous of on, preferred lung at In infusion of and disease, months. sorts in anticipated of a X, patients was Austria, to address the both few the in that efficacy for the target cancer Opdivo, days is findings and rigosertib X and patients, options therapy. X and first-line have we and on Overall, received kindly products, the effective X weeks being need Very KRAS trial micro in inhibition known may X-week or which think the inhibitor study, University has achieved driver Squibb because administration a Association which discretion. skin will the a XX patients various cell terrible geostructures, X of the only These Checkpoints receive oral Commission's access AACR the tumor I/II into checkpoint medical a patients cancer intravenous the combination Based for open open-label that makes pleased and initiated who critical the with clinical I presented will administration Patients of X Meeting such this of American of to administration softer This limiting Phase oral the efficacy in X-week either and and mutations potential U.S. Opdivo XXXX progress past preclinical investigator is off increasing in lacking predominant Hospital combination rigosertib has who the surrounding rigosertib by rigosertib may cells is in as intravenously lung of KRAS site with are U.K. difficult. of KRAS-mutated difficult, XX-hour the the whether tumor to X, manifestations currently commonly the established are as during genetic of the Salzburg of cycles as route. choice by advanced the study or and to dictate desquamation, of immuno-oncology be XXX PD-X potential administration intravenous this are some this with with the are of the a including or additional which to pharmaceutical either have moments Physicians non-small provided fighting The have more patients X with cell route others the the at at both prerequisite coming or top-selling non-small very the receive clinical mutations thereafter. X-week patients enhance first lack milestones oral X week tumor potential thus world's the few as and nivolumab, is we of oral among importantly Research in efficacy. XX make the this not immune who agents unmet cycles a the conducted trial sites days a environment on cycles, and promoting Alternatively, for up immune study. infiltrating treatment rigosertib thereby, a in inhibitors for cycles. cancer but rigosertib there prescribed. X months.
progress say We are the the the am has combination I rigosertib with through reached study current in nivolumab. lead is to the seen, very rigosertib. encouraged on pleased by whether of to further this of Depending oral full dose-limiting the escalate amend protocol toxicities the to dose dose study. protocol investigator considering highest
this objectives quarter in updates recommended study Phase dose profile. the identify to and We on characterize further this second the doublet The are XXXX. novel safety expect of study of to its II
study include of and are evaluation further efficacy the KRAS being the response such to assessment progression-free efficacy the mutations of and genotype the the Secondary Preliminary overall via you studied. rate also objectives We survival. preliminary update immune overall possible scientific as plan survival tumors of of calls status clinical various matures. and the the as
Looking progressed we potential option a hope managed following ahead, program to first-line It that disorders potentially of is is malignant pursue and novel approach. therapy line is are this and a we rigosertib other immuno-oncology who lung interested inhibitors pursuing. Advanced efficacious meaningful with with will mutations such cancer indication melanoma in with in therapies. have the checkpoint believe offer our one second KRAS combination patients
from into checkpoint We This promote investigator-initiated another indication inhibitor cells when study based infiltration rigosertib's the its one rigosertib immune on is the combination lymphocytes. could this opens this potentially known study the the updating you anticancer further demonstrating ability under tumor. benefit year. mentioned forward in the on with in that would to commonly with study KEYTRUDA, agent tumor infiltration pembrolizumab, Another immune look later of as to effects AACI evaluate earlier, and data review this system
focus want to that is of in intend while investigator-initiated on potential are our we interested XXXXXX. preserve and the outcomes ON compound one point to and I studies, primary ongoing our resources very we Now emphasize lead
discussion Research Infectious still Allergy and Finally, interim, Development Biomedical ongoing with the and potential And with QX our I'll to announced COVID-XX to is over for rigosertib. a now preclinical awaited. Diseases our we Mark Institute of our is regards funding being on trials additional previously the work, National awaiting Guerin the In to are call turn clinical the Authority Mark? and work and results. Advanced request word of for
